Investigational Drug Details
| Drug ID: | D019 |
| Drug Name: | Astaxanthin |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB06543 |
| DrugBank Description: | Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may be found in fish feed or some animal food as a color additive. |
| PubChem ID: | 5281224 |
| CasNo: | 472-61-7 |
| Repositioning for NAFLD: | No |
| SMILES: | C(=C\C(=C\C=C\C(=C\C=C\C=C(\C=C\C=C(\C=C\C1=C(C)C(=O)[C@H](CC1(C)C)O)/C)/C)\C)\C)/C1=C(C)C(=O)[C@H](CC1(C)C)O |
| Structure: |
|
| InChiKey: | MQZIGYBFDRPAKN-UWFIBFSHSA-N |
| Molecular Weight: | 596.852 |
| DrugBank Targets: | NF-kappa-B inhibitor alpha |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | Investigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma. |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (JPRN-UMIN000008524) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0652 | JPRN-UMIN000008524 | Not selected | Recruiting | No Results Available | 24/07/2012 | 2 April 2019 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01601 | 34681695 | Int J Mol Sci | Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. | Details |
| A01698 | 34651285 | J Physiol Biochem | Astaxanthin attenuates hepatic steatosis in high-fat diet-fed rats by suppressing microRNA-21 via transactivation of nuclear factor erythroid 2-related factor 2. | Details |
| A03513 | 33974978 | Free Radic Biol Med | Effects of astaxanthin in animal models of obesity-associated diseases: A systematic review and meta-analysis. | Details |
| A04030 | 33783746 | Adv Exp Med Biol | Prevention of NAFLD/NASH by Astaxanthin and β-Cryptoxanthin. | Details |
| A04394 | 33636349 | Pharmacol Res | Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. | Details |
| A07138 | 32606597 | Drug Des Devel Ther | Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent. | Details |
| A07548 | 32446270 | Br J Pharmacol | Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1α pathway. | Details |
| A09014 | 31904420 | Biochim Biophys Acta Mol Cell Biol Lipids | Carotenoids and fatty liver disease: Current knowledge and research gaps. | Details |
| A10458 | 31328113 | Prev Nutr Food Sci | Health Benefits of Carotenoids: A Role of Carotenoids in the Prevention of Non-Alcoholic Fatty Liver Disease. | Details |
| A13089 | 30142943 | Nutrients | Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. | Details |
| A14731 | 29268106 | J Nutr Biochem | Food components with antifibrotic activity and implications in prevention of liver disease. | Details |
| A15042 | 29121675 | PLoS One | Astaxanthin prevents ischemia-reperfusion injury of the steatotic liver in mice. | Details |
| A15819 | 28694655 | World J Gastroenterol | Antioxidant dietary approach in treatment of fatty liver: New insights and updates. | Details |
| A16269 | 28475150 | Int J Mol Sci | Reply to the Letter to the Editor by Li et al.: Bioinformatics Analysis in Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E. | Details |
| A16287 | 28471394 | Int J Mol Sci | Letter to the Editor: Bioinformatics Analysis in Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E. | Details |
| A16394 | 28420094 | Nutrients | Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. | Details |
| A16527 | 28335388 | Nutrients | A Combination of Flaxseed Oil and Astaxanthin Improves Hepatic Lipid Accumulation and Reduces Oxidative Stress in High Fat-Diet Fed Rats. | Details |
| A16614 | 28282876 | Int J Mol Sci | Hepatic Transcriptome Profiles of Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E. | Details |
| A16767 | 28193580 | J Nutr Biochem | Astaxanthin inhibits inflammation and fibrosis in the liver and adipose tissue of mouse models of diet-induced obesity and nonalcoholic steatohepatitis. | Details |
| A17340 | 27834813 | Biology (Basel) | The Potential of Non-Provitamin A Carotenoids for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease. | Details |